位置:首页 > 蛋白库 > GDIR1_HUMAN
GDIR1_HUMAN
ID   GDIR1_HUMAN             Reviewed;         204 AA.
AC   P52565; A8MXW0; B2R5X1; B4DDD3; B4DUV9; Q6IBM5;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   03-AUG-2022, entry version 205.
DE   RecName: Full=Rho GDP-dissociation inhibitor 1;
DE            Short=Rho GDI 1;
DE   AltName: Full=Rho-GDI alpha;
GN   Name=ARHGDIA; Synonyms=GDIA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8262133; DOI=10.1006/excr.1993.1298;
RA   Leffers H., Nielsen M.S., Andersen A.H., Honore B., Madsen P.,
RA   Vandekerckhove J., Celis J.E.;
RT   "Identification of two human Rho GDP dissociation inhibitor proteins whose
RT   overexpression leads to disruption of the actin cytoskeleton.";
RL   Exp. Cell Res. 209:165-174(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Maeda A., Kaibuchi K., Takai Y.;
RT   "Molecular cloning of human rho GDI.";
RL   Submitted (APR-1993) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Chuang T.H., Bokoch G.M.;
RT   "cDNA sequence of human rho GDP dissociation inhibitor.";
RL   Submitted (JUL-1992) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RA   Mulheron J.G., Schwinn D.A., Caron M.G., Liggett S.B.;
RT   "Genomic sequence of a human rho GDP dissociation inhibitor (GDI).";
RL   Submitted (MAR-1992) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain cortex, and Neuroblastoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon, Lung, Muscle, Skin, Tonsil, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   PROTEIN SEQUENCE OF 2-42, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT
RP   ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=T-cell;
RA   Bienvenut W.V., Kanor S., Tissot J.-D., Quadroni M.;
RL   Submitted (MAY-2006) to UniProtKB.
RN   [13]
RP   PROTEIN SEQUENCE OF 34-50; 139-167 AND 181-199, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [14]
RP   PROTEIN SEQUENCE OF 34-37; 136-142 AND 181-199.
RC   TISSUE=Neutrophil;
RX   PubMed=8504089; DOI=10.1021/bi00072a029;
RA   Kwong C.H., Malech H.L., Rotrosen D., Leto T.L.;
RT   "Regulation of the human neutrophil NADPH oxidase by rho-related G-
RT   proteins.";
RL   Biochemistry 32:5711-5717(1993).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-141, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16916647; DOI=10.1016/j.molcel.2006.06.026;
RA   Kim S.C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T., Kho Y.,
RA   Xiao H., Xiao L., Grishin N.V., White M., Yang X.-J., Zhao Y.;
RT   "Substrate and functional diversity of lysine acetylation revealed by a
RT   proteomics survey.";
RL   Mol. Cell 23:607-618(2006).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-105; LYS-127; LYS-141 AND
RP   LYS-178, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [18]
RP   INTERACTION WITH FER.
RX   PubMed=21122136; DOI=10.1186/1471-2091-11-48;
RA   Fei F., Kweon S.M., Haataja L., De Sepulveda P., Groffen J.,
RA   Heisterkamp N.;
RT   "The Fer tyrosine kinase regulates interactions of Rho GDP-Dissociation
RT   Inhibitor alpha with the small GTPase Rac.";
RL   BMC Biochem. 11:48-48(2010).
RN   [19]
RP   INTERACTION WITH PSMD10 AND RHOA.
RX   PubMed=20628200; DOI=10.1172/jci42542;
RA   Man J.H., Liang B., Gu Y.X., Zhou T., Li A.L., Li T., Jin B.F., Bai B.,
RA   Zhang H.Y., Zhang W.N., Li W.H., Gong W.L., Li H.Y., Zhang X.M.;
RT   "Gankyrin plays an essential role in Ras-induced tumorigenesis through
RT   regulation of the RhoA/ROCK pathway in mammalian cells.";
RL   J. Clin. Invest. 120:2829-2841(2010).
RN   [20]
RP   FUNCTION, INTERACTION WITH RHOA AND RHOC, AND MUTAGENESIS OF ASP-45 AND
RP   ASP-185.
RX   PubMed=20400958; DOI=10.1038/ncb2049;
RA   Boulter E., Garcia-Mata R., Guilluy C., Dubash A., Rossi G.,
RA   Brennwald P.J., Burridge K.;
RT   "Regulation of Rho GTPase crosstalk, degradation and activity by RhoGDI1.";
RL   Nat. Cell Biol. 12:477-483(2010).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [25]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-138 AND LYS-141, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [26]
RP   INTERACTION WITH KANK2.
RX   PubMed=25961457; DOI=10.1172/jci79504;
RA   Gee H.Y., Zhang F., Ashraf S., Kohl S., Sadowski C.E., Vega-Warner V.,
RA   Zhou W., Lovric S., Fang H., Nettleton M., Zhu J.Y., Hoefele J.,
RA   Weber L.T., Podracka L., Boor A., Fehrenbach H., Innis J.W., Washburn J.,
RA   Levy S., Lifton R.P., Otto E.A., Han Z., Hildebrandt F.;
RT   "KANK deficiency leads to podocyte dysfunction and nephrotic syndrome.";
RL   J. Clin. Invest. 125:2375-2384(2015).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 59-204.
RX   PubMed=9195882; DOI=10.1016/s0969-2126(97)00218-9;
RA   Keep N.H., Barnes M., Barsukov I., Badii R., Lian L.-Y., Segal A.W.,
RA   Moody P.C.E., Roberts G.C.K.;
RT   "A modulator of rho family G proteins, rhoGDI, binds these G proteins via
RT   an immunoglobulin-like domain and a flexible N-terminal arm.";
RL   Structure 5:623-633(1997).
RN   [29] {ECO:0007744|PDB:2N80}
RP   STRUCTURE BY NMR OF 31-204 IN COMPLEX WITH NGFR, INTERACTION WITH RHOA AND
RP   NGFR, AND MUTAGENESIS OF LYS-99 AND LYS-199.
RX   PubMed=26646181; DOI=10.7554/elife.11692;
RA   Lin Z., Tann J.Y., Goh E.T., Kelly C., Lim K.B., Gao J.F., Ibanez C.F.;
RT   "Structural basis of death domain signaling in the p75 neurotrophin
RT   receptor.";
RL   Elife 4:e11692-e11692(2015).
RN   [30]
RP   VARIANT NPHS8 ASP-185 DEL, CHARACTERIZATION OF VARIANT NPHS8 ASP-185 DEL,
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH RAC1; RHOA AND CDC42.
RX   PubMed=23434736; DOI=10.1136/jmedgenet-2012-101442;
RA   Gupta I.R., Baldwin C., Auguste D., Ha K.C., El Andalousi J.,
RA   Fahiminiya S., Bitzan M., Bernard C., Akbari M.R., Narod S.A.,
RA   Rosenblatt D.S., Majewski J., Takano T.;
RT   "ARHGDIA: a novel gene implicated in nephrotic syndrome.";
RL   J. Med. Genet. 50:330-338(2013).
CC   -!- FUNCTION: Controls Rho proteins homeostasis. Regulates the GDP/GTP
CC       exchange reaction of the Rho proteins by inhibiting the dissociation of
CC       GDP from them, and the subsequent binding of GTP to them. Retains Rho
CC       proteins such as CDC42, RAC1 and RHOA in an inactive cytosolic pool,
CC       regulating their stability and protecting them from degradation.
CC       Actively involved in the recycling and distribution of activated Rho
CC       GTPases in the cell, mediates extraction from membranes of both
CC       inactive and activated molecules due its exceptionally high affinity
CC       for prenylated forms. Through the modulation of Rho proteins, may play
CC       a role in cell motility regulation. In glioma cells, inhibits cell
CC       migration and invasion by mediating the signals of SEMA5A and PLXNB3
CC       that lead to inactivation of RAC1. {ECO:0000269|PubMed:20400958,
CC       ECO:0000269|PubMed:23434736}.
CC   -!- SUBUNIT: Monomer (By similarity). Interacts with FER (PubMed:21122136).
CC       Interacts with PLXNB3 (By similarity). Forms a heterodimer with RAC1
CC       (PubMed:23434736). Interacts with RHOA, the affinity is increased by
CC       three orders of magnitude when RHOA is prenylated (PubMed:20628200,
CC       PubMed:20400958, PubMed:26646181, PubMed:23434736). Interacts with
CC       PSMD10; the interaction increases ARHGDIA association with RHOA,
CC       leading to ARHGDIA-mediated inactivation of RHOA and ROCK and prolonged
CC       AKT activation (PubMed:20628200). Interacts with KANK2; the interaction
CC       is direct and may regulate the interaction of ARHGDIA with RHOA, RAC1
CC       and CDC42 (PubMed:25961457). Interacts with RHOC (PubMed:20400958).
CC       Interacts with CDC42 (PubMed:23434736). Interacts with NGFR (via death
CC       domain); NGFR binding decreases the affinity for RHOA
CC       (PubMed:26646181). {ECO:0000250|UniProtKB:Q99PT1,
CC       ECO:0000269|PubMed:20400958, ECO:0000269|PubMed:20628200,
CC       ECO:0000269|PubMed:21122136, ECO:0000269|PubMed:23434736,
CC       ECO:0000269|PubMed:25961457, ECO:0000269|PubMed:26646181}.
CC   -!- INTERACTION:
CC       P52565; P60953: CDC42; NbExp=4; IntAct=EBI-712693, EBI-81752;
CC       P52565; P63000: RAC1; NbExp=9; IntAct=EBI-712693, EBI-413628;
CC       P52565; P61586: RHOA; NbExp=5; IntAct=EBI-712693, EBI-446668;
CC       P52565; Q9BSI4: TINF2; NbExp=2; IntAct=EBI-712693, EBI-717399;
CC       P52565; Q9NS68: TNFRSF19; NbExp=3; IntAct=EBI-712693, EBI-530381;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:23434736}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P52565-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P52565-2; Sequence=VSP_046699;
CC   -!- DISEASE: Nephrotic syndrome 8 (NPHS8) [MIM:615244]: A form of nephrotic
CC       syndrome, a renal disease clinically characterized by progressive renal
CC       failure, severe proteinuria, hypoalbuminemia, hyperlipidemia and edema.
CC       Kidney biopsies show diffuse mesangial sclerosis, with small glomeruli,
CC       hypercellularity, increased extracellular matrix, and
CC       contracted/collapsed glomerular tufts surrounded by immature or
CC       abnormal podocytes. {ECO:0000269|PubMed:23434736}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the Rho GDI family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X69550; CAA49281.1; -; mRNA.
DR   EMBL; D13989; BAA03096.1; -; mRNA.
DR   EMBL; M97579; AAA36566.1; -; mRNA.
DR   EMBL; X63863; CAA45344.1; -; Genomic_DNA.
DR   EMBL; AK300816; BAG62471.1; -; mRNA.
DR   EMBL; AK312347; BAG35268.1; -; mRNA.
DR   EMBL; AF498926; AAM21074.1; -; mRNA.
DR   EMBL; BT006884; AAP35530.1; -; mRNA.
DR   EMBL; CR456777; CAG33058.1; -; mRNA.
DR   EMBL; AC145207; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471099; EAW89697.1; -; Genomic_DNA.
DR   EMBL; BC005851; AAH05851.1; -; mRNA.
DR   EMBL; BC005875; AAH05875.1; -; mRNA.
DR   EMBL; BC008701; AAH08701.1; -; mRNA.
DR   EMBL; BC009759; AAH09759.1; -; mRNA.
DR   EMBL; BC016031; AAH16031.1; -; mRNA.
DR   EMBL; BC016185; AAH16185.1; -; mRNA.
DR   EMBL; BC024258; AAH24258.1; -; mRNA.
DR   EMBL; BC027730; AAH27730.1; -; mRNA.
DR   EMBL; BC075827; AAH75827.1; -; mRNA.
DR   EMBL; BC106044; AAI06045.1; -; mRNA.
DR   CCDS; CCDS11788.1; -. [P52565-1]
DR   CCDS; CCDS58609.1; -. [P52565-2]
DR   PIR; I38156; I38156.
DR   RefSeq; NP_001172006.1; NM_001185077.2. [P52565-1]
DR   RefSeq; NP_001172007.1; NM_001185078.2. [P52565-2]
DR   RefSeq; NP_001288169.1; NM_001301240.1.
DR   RefSeq; NP_001288170.1; NM_001301241.1.
DR   RefSeq; NP_001288171.1; NM_001301242.1.
DR   RefSeq; NP_001288172.1; NM_001301243.1.
DR   RefSeq; NP_004300.1; NM_004309.5. [P52565-1]
DR   PDB; 1CC0; X-ray; 5.00 A; E/F=1-204.
DR   PDB; 1FSO; X-ray; 2.00 A; A=67-204.
DR   PDB; 1FST; X-ray; 2.70 A; A/B=24-204.
DR   PDB; 1FT0; X-ray; 2.60 A; A/B=67-204.
DR   PDB; 1FT3; X-ray; 2.80 A; A/B=67-204.
DR   PDB; 1HH4; X-ray; 2.70 A; D/E=1-204.
DR   PDB; 1KMT; X-ray; 1.30 A; A/B=67-204.
DR   PDB; 1QVY; X-ray; 1.60 A; A/B/C/D=67-204.
DR   PDB; 1RHO; X-ray; 2.50 A; A/B/C=59-203.
DR   PDB; 2BXW; X-ray; 2.40 A; A/B=67-204.
DR   PDB; 2JHS; X-ray; 1.95 A; A=67-202.
DR   PDB; 2JHT; X-ray; 1.88 A; A/B/C/D=67-202.
DR   PDB; 2JHU; X-ray; 1.65 A; A/B=67-202.
DR   PDB; 2JHV; X-ray; 2.07 A; A/B/C/D/E/F=67-202.
DR   PDB; 2JHW; X-ray; 2.50 A; A/B=67-202.
DR   PDB; 2JHX; X-ray; 1.60 A; A/B=67-202.
DR   PDB; 2JHY; X-ray; 1.90 A; A=67-202.
DR   PDB; 2JHZ; X-ray; 2.20 A; A/B=67-202.
DR   PDB; 2JI0; X-ray; 2.10 A; A=67-202.
DR   PDB; 2N80; NMR; -; B=31-204.
DR   PDBsum; 1CC0; -.
DR   PDBsum; 1FSO; -.
DR   PDBsum; 1FST; -.
DR   PDBsum; 1FT0; -.
DR   PDBsum; 1FT3; -.
DR   PDBsum; 1HH4; -.
DR   PDBsum; 1KMT; -.
DR   PDBsum; 1QVY; -.
DR   PDBsum; 1RHO; -.
DR   PDBsum; 2BXW; -.
DR   PDBsum; 2JHS; -.
DR   PDBsum; 2JHT; -.
DR   PDBsum; 2JHU; -.
DR   PDBsum; 2JHV; -.
DR   PDBsum; 2JHW; -.
DR   PDBsum; 2JHX; -.
DR   PDBsum; 2JHY; -.
DR   PDBsum; 2JHZ; -.
DR   PDBsum; 2JI0; -.
DR   PDBsum; 2N80; -.
DR   AlphaFoldDB; P52565; -.
DR   SMR; P52565; -.
DR   BioGRID; 106889; 145.
DR   ELM; P52565; -.
DR   IntAct; P52565; 56.
DR   MINT; P52565; -.
DR   STRING; 9606.ENSP00000269321; -.
DR   ChEMBL; CHEMBL3638327; -.
DR   GlyGen; P52565; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P52565; -.
DR   MetOSite; P52565; -.
DR   PhosphoSitePlus; P52565; -.
DR   SwissPalm; P52565; -.
DR   BioMuta; ARHGDIA; -.
DR   DMDM; 1707892; -.
DR   DOSAC-COBS-2DPAGE; P52565; -.
DR   OGP; P52565; -.
DR   REPRODUCTION-2DPAGE; IPI00003815; -.
DR   EPD; P52565; -.
DR   jPOST; P52565; -.
DR   MassIVE; P52565; -.
DR   MaxQB; P52565; -.
DR   PaxDb; P52565; -.
DR   PeptideAtlas; P52565; -.
DR   PRIDE; P52565; -.
DR   ProteomicsDB; 2358; -.
DR   ProteomicsDB; 56489; -. [P52565-1]
DR   TopDownProteomics; P52565-1; -. [P52565-1]
DR   Antibodypedia; 3880; 580 antibodies from 39 providers.
DR   DNASU; 396; -.
DR   Ensembl; ENST00000269321.12; ENSP00000269321.7; ENSG00000141522.12. [P52565-1]
DR   Ensembl; ENST00000400721.8; ENSP00000383556.4; ENSG00000141522.12. [P52565-2]
DR   Ensembl; ENST00000541078.6; ENSP00000441348.2; ENSG00000141522.12. [P52565-1]
DR   Ensembl; ENST00000580685.5; ENSP00000464205.1; ENSG00000141522.12. [P52565-1]
DR   GeneID; 396; -.
DR   KEGG; hsa:396; -.
DR   MANE-Select; ENST00000269321.12; ENSP00000269321.7; NM_004309.6; NP_004300.1.
DR   UCSC; uc021ufg.2; human. [P52565-1]
DR   CTD; 396; -.
DR   DisGeNET; 396; -.
DR   GeneCards; ARHGDIA; -.
DR   HGNC; HGNC:678; ARHGDIA.
DR   HPA; ENSG00000141522; Low tissue specificity.
DR   MalaCards; ARHGDIA; -.
DR   MIM; 601925; gene.
DR   MIM; 615244; phenotype.
DR   neXtProt; NX_P52565; -.
DR   OpenTargets; ENSG00000141522; -.
DR   Orphanet; 656; Genetic steroid-resistant nephrotic syndrome.
DR   PharmGKB; PA24963; -.
DR   VEuPathDB; HostDB:ENSG00000141522; -.
DR   eggNOG; KOG3205; Eukaryota.
DR   GeneTree; ENSGT00390000006233; -.
DR   HOGENOM; CLU_076228_1_1_1; -.
DR   InParanoid; P52565; -.
DR   OMA; DDDKRCH; -.
DR   OrthoDB; 1265661at2759; -.
DR   PhylomeDB; P52565; -.
DR   TreeFam; TF105387; -.
DR   PathwayCommons; P52565; -.
DR   Reactome; R-HSA-193634; Axonal growth inhibition (RHOA activation).
DR   Reactome; R-HSA-209563; Axonal growth stimulation.
DR   Reactome; R-HSA-8980692; RHOA GTPase cycle.
DR   Reactome; R-HSA-9013106; RHOC GTPase cycle.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013404; RAC2 GTPase cycle.
DR   Reactome; R-HSA-9013407; RHOH GTPase cycle.
DR   Reactome; R-HSA-9013408; RHOG GTPase cycle.
DR   SignaLink; P52565; -.
DR   SIGNOR; P52565; -.
DR   BioGRID-ORCS; 396; 34 hits in 1081 CRISPR screens.
DR   ChiTaRS; ARHGDIA; human.
DR   EvolutionaryTrace; P52565; -.
DR   GeneWiki; ARHGDIA; -.
DR   GenomeRNAi; 396; -.
DR   Pharos; P52565; Tchem.
DR   PRO; PR:P52565; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P52565; protein.
DR   Bgee; ENSG00000141522; Expressed in granulocyte and 202 other tissues.
DR   ExpressionAtlas; P52565; baseline and differential.
DR   Genevisible; P52565; HS.
DR   GO; GO:0005856; C:cytoskeleton; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0001772; C:immunological synapse; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005096; F:GTPase activator activity; IEA:UniProtKB-KW.
DR   GO; GO:0005094; F:Rho GDP-dissociation inhibitor activity; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; TAS:ProtInc.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; IMP:UniProtKB.
DR   GO; GO:0032880; P:regulation of protein localization; IEA:Ensembl.
DR   GO; GO:0035023; P:regulation of Rho protein signal transduction; IMP:UniProtKB.
DR   GO; GO:0007266; P:Rho protein signal transduction; IBA:GO_Central.
DR   GO; GO:0071526; P:semaphorin-plexin signaling pathway; ISS:UniProtKB.
DR   Gene3D; 2.70.50.30; -; 1.
DR   IDEAL; IID00273; -.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR000406; Rho_GDI.
DR   InterPro; IPR024792; RhoGDI_dom_sf.
DR   PANTHER; PTHR10980; PTHR10980; 1.
DR   Pfam; PF02115; Rho_GDI; 1.
DR   PRINTS; PR00492; RHOGDI.
DR   SUPFAM; SSF81296; SSF81296; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cytoplasm;
KW   Direct protein sequencing; Disease variant; GTPase activation;
KW   Isopeptide bond; Phosphoprotein; Reference proteome; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.12, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:20068231"
FT   CHAIN           2..204
FT                   /note="Rho GDP-dissociation inhibitor 1"
FT                   /id="PRO_0000219013"
FT   REGION          1..36
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|Ref.12, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         34
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PT1"
FT   MOD_RES         43
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PT1"
FT   MOD_RES         47
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         105
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         127
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         141
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:16916647,
FT                   ECO:0007744|PubMed:19608861"
FT   MOD_RES         141
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PT1"
FT   MOD_RES         178
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   CROSSLNK        138
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        138
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        141
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        141
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   VAR_SEQ         139..183
FT                   /note="IDKTDYMVGSYGPRAEEYEFLTPVEEAPKGMLARGSYSIKSRFTD -> N
FT                   (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046699"
FT   VARIANT         185
FT                   /note="Missing (in NPHS8; produces mislocalization into the
FT                   nucleus, hyperactivation of Rho-GTPases RHOA, RAC1 and
FT                   CDC42 and impaired cell motility)"
FT                   /evidence="ECO:0000269|PubMed:23434736"
FT                   /id="VAR_069814"
FT   MUTAGEN         45
FT                   /note="D->A: Loss of RHOA interaction; when associated with
FT                   A-185."
FT                   /evidence="ECO:0000269|PubMed:20400958"
FT   MUTAGEN         99
FT                   /note="K->A: Loss of interaction with NGFR."
FT                   /evidence="ECO:0000269|PubMed:26646181"
FT   MUTAGEN         185
FT                   /note="D->A: Loss of RHOA interaction; when associated with
FT                   A-45."
FT                   /evidence="ECO:0000269|PubMed:20400958"
FT   MUTAGEN         199
FT                   /note="K->A: Loss of interaction with NGFR."
FT                   /evidence="ECO:0000269|PubMed:26646181"
FT   CONFLICT        139
FT                   /note="I -> V (in Ref. 3; CAA45344 and 5; BAG35268)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        188
FT                   /note="D -> R (in Ref. 13; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   HELIX           35..39
FT                   /evidence="ECO:0007829|PDB:1HH4"
FT   HELIX           46..56
FT                   /evidence="ECO:0007829|PDB:1HH4"
FT   TURN            59..63
FT                   /evidence="ECO:0007829|PDB:2N80"
FT   STRAND          69..78
FT                   /evidence="ECO:0007829|PDB:1KMT"
FT   STRAND          82..84
FT                   /evidence="ECO:0007829|PDB:1KMT"
FT   STRAND          87..89
FT                   /evidence="ECO:0007829|PDB:1KMT"
FT   HELIX           94..99
FT                   /evidence="ECO:0007829|PDB:1KMT"
FT   STRAND          102..105
FT                   /evidence="ECO:0007829|PDB:1KMT"
FT   STRAND          109..118
FT                   /evidence="ECO:0007829|PDB:1KMT"
FT   STRAND          123..134
FT                   /evidence="ECO:0007829|PDB:1KMT"
FT   STRAND          137..149
FT                   /evidence="ECO:0007829|PDB:1KMT"
FT   STRAND          156..159
FT                   /evidence="ECO:0007829|PDB:1KMT"
FT   TURN            169..171
FT                   /evidence="ECO:0007829|PDB:1KMT"
FT   STRAND          173..182
FT                   /evidence="ECO:0007829|PDB:1KMT"
FT   STRAND          189..200
FT                   /evidence="ECO:0007829|PDB:1KMT"
SQ   SEQUENCE   204 AA;  23207 MW;  59CB6F42E3B3BCCA CRC64;
     MAEQEPTAEQ LAQIAAENEE DEHSVNYKPP AQKSIQEIQE LDKDDESLRK YKEALLGRVA
     VSADPNVPNV VVTGLTLVCS SAPGPLELDL TGDLESFKKQ SFVLKEGVEY RIKISFRVNR
     EIVSGMKYIQ HTYRKGVKID KTDYMVGSYG PRAEEYEFLT PVEEAPKGML ARGSYSIKSR
     FTDDDKTDHL SWEWNLTIKK DWKD
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024